Sign up Australia
Proactive Investors - Run By Investors For Investors

Actinogen Medical enrols first UK patient in Alzheimer’s therapy trial

The annual cost of managing Alzheimer’s disease is estimated to be US$250B in the U.S.
Actinogen Medical enrols first UK patient in Alzheimer’s therapy trial
The patient in UK was enrolled at St. Pancras Clinical Research in London

Actinogen Medical (ASX:ACW) has enrolled its first UK patient into XanADu, its international Phase II efficacy and safety trial of Xanamem therapy in patients with mild Alzheimer’s disease.

Xanamem has been specifically designed to block the excess production of cortisol, the stress hormone, in the areas of the brain most affected by Alzheimer’s disease.

The patient in UK was enrolled at St. Pancras Clinical Research in London. This is the sixteenth patient to be enrolled globally across the eighteen research sites currently open.

Actinogen’s trial will enrol 174 patients at 20 research sites across Australia, the U.S. and the UK.

To-date, over 50 patients have been screened for the study, with at least half expected to progress to enrolment into the trial.

The first XanADu patient will complete the study next month, having reached the end of the 12-week dosing period, and now entering the 4-week follow up phase of the trial.

It is estimated that there are nearly 50 million people with Alzheimer’s disease worldwide, increasing to 131 million by 2050, making it critical to find effective new drugs to treat the disease.

The progress in the development of Xanamem is expected to provide an opportunity for Actinogen to make a profound difference to Alzheimer’s patients and their carers worldwide.

Actinogen ended the June quarter with $3.98 million in cash.

View full ACW profile View Profile

Actinogen Medical Ltd Timeline

December 30 2016

Related Articles

Graphic of person pointing to different parts of the body
May 14 2018
Paradigm’s share price has increased more than 60% in the last month and it was up more than 12% on Friday.
cancer cells from taken by an electron microscope
March 13 2018
Sareum has partnered with Sierra Oncology to advance the company's Checkpoint kinase 1 inhibitor
People working in a laboratory
May 02 2018
The benefits of Admedus' proprietary ADAPT technology and products are now scientifically proven beyond doubt.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use